JACOBI MEDICAL CENTER

ESMO 2024: Key Breast Cancer Advances Highlighted

8 months ago

• Final KEYNOTE-522 data confirmed pembrolizumab's benefit in neoadjuvant chemotherapy for early-stage triple-negative breast cancer, improving 5-year overall survival. • NATALEE trial's 4-year update showed ribociclib plus aromatase inhibition significantly improved invasive disease-free survival in high-risk, hormone receptor-positive early breast cancer. • DESTINY-Breast12 trial demonstrated trastuzumab deruxtecan's significant intracranial activity in HER2-positive metastatic breast cancer patients with brain metastases. • ICARUS-BREAST01 trial revealed promising objective response rates and progression-free survival with patritumab deruxtecan in HER3-positive, hormone receptor-positive, HER2-negative metastatic breast cancer.

CAR T-cell Therapy Demonstrates Superior Overall Survival Compared to Bispecific Antibody in Multiple Myeloma

8 months ago

• A real-world study comparing CAR T-cell therapies (ide-cel and cilta-cel) to the bispecific antibody teclistamab in multiple myeloma patients showed improved overall survival with CAR T. • The CAR T cohort experienced a lower mortality rate (20%) compared to the teclistamab cohort (30%) after one year of follow-up, with a hazard ratio of 0.62 (95% CI, 0.38-0.99). • While CAR T therapy was associated with a higher risk of cytokine release syndrome (CRS), no significant differences in neurotoxicity were observed between the two treatment approaches. • The study suggests that upfront BCMA-targeted CAR T-cell therapy may improve survival outcomes, especially in older, transplant-ineligible patients with multiple myeloma.